Key result
Tissue-engineered semilunar heart valve substitutes are being developed as promising alternatives to current replacement options, with advancements in cell sources, scaffolds, and bioreactors.
Tissue engineering offers promising alternatives to current heart valve replacements by utilizing novel cell sources, scaffolds, and biomimetic bioreactors.
Advances in tissue-engineered valves remain preclinical; leaves open need for randomized trials before clinical use.
Heart valve disease is a significant medical problem worldwide. Current treatment for heart valve disease is heart valve replacement. State of the art replacement heart valves are less than ideal and are associated with significant complications. Using the basic principles of tissue engineering, promising alternatives to current replacement heart valves are being developed. Significant progress has been made in the development of a tissue-engineered semilunar heart valve substitute. Advancements include the development of different potential cell sources and cell-seeding techniques; advancements in matrix and scaffold development and in polymer chemistry fabrication; and the development of a variety of bioreactors, which are biomimetic devices used to modulate the development of tissue-engineered neotissue in vitro through the application of biochemical and biomechanical stimuli. This review addresses the need for a tissue-engineered alternative to the current heart valve replacement options. The basics of heart valve structure and function, heart valve disease, and currently available heart valve replacements are discussed. The last 10 years of investigation into a tissue-engineered heart valve as well as current developments are reviewed. Finally, the early clinical applications of cardiovascular tissue engineering are presented.
No takes yet. Share an insight, caveat, or question.
Breuer et al. (2004) conducted a review in Heart valve disease. Tissue-engineered semilunar heart valve substitute vs. Current heart valve replacement options was evaluated. Tissue-engineered semilunar heart valve substitutes are being developed as promising alternatives to current replacement options, with advancements in cell sources, scaffolds, and bioreactors.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: